Up-regulation of SLC9A9 promotes cancer progression and is involved in poor prognosis in colorectal cancer

Masami Ueda, Tomohiro Iguchi, Takaaki Masuda, Hisateru Komatsu, Sho Nambara, Shotaro Sakimura, Hidenari Hirata, Ryutaro Uchi, Hidetoshi Eguchi, Shuhei Ito, Keishi Sugimachi, Tsunekazu Mizushima, Yuichiro Doki, Masaki Mori, Koshi Mimori

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aim: SLC9A9 plays an oncogenic role in esophageal squamous carcinoma and glioblastoma. Herein, we showed an oncogenic function of SLC9A9 in colorectal cancer (CRC). Materials and Methods: We examined SLC9A9 expression in CRC specimens by immunohistochemistry. In CRC tissues, the relationship between SLC9A9 expression and clinicopathological factors was further elucidated by quantitative real-time polymerase chain reaction (qRT-PCR) and gene set enrichment analysis (GSEA). In vitro, we performed knockdown and overexpression experiments. Results: SLC9A9 was overexpressed in CRC specimens. In clinicopathological analysis of our cohort, high SLC9A9 expression increased liver metastasis and was correlated with worse prognoses in two cohorts. A significantly positive relationship between SLC9A9 and EGFR was revealed. While knockdown of SLC9A9 suppressed proliferation and anchorageindependent growth, up-regulation of SLC9A9 promoted proliferation and anchorage-independent growth in vitro. Conclusion: SLC9A9 has an oncogenic function by being related to EGFR signaling, suggesting SLC9A9 may be a novel prognostic indicator and a therapeutic target in CRC.

Original languageEnglish
Pages (from-to)2255-2263
Number of pages9
JournalAnticancer research
Volume37
Issue number5
DOIs
Publication statusPublished - May 2017

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this